Skip to main content
. 2023 Aug 8;10:1243843. doi: 10.3389/fmed.2023.1243843

Table 2.

Safety profile of bimekizumab throughout the study period.

Event No. (%)
Any AE 59 (24.9)
Severe AE 0
AE leading to discontinuation 2 (0.8)
Upper Respiratory Tract Infection 20 (8.4)
Oral Candidiasis 24 (10.1)
Nasopharyngitis 9 (3.8)
Diarrhea 2 (0.8)
Eczematous Reaction 2 (0.8)

AE, adverse event.